Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003
Braz. j. infect. dis
;
9(3): 216-224, Jun. 2005. tab
Artículo
en Inglés
| LILACS
| ID: lil-412879
ABSTRACT
Establish the susceptibility pattern of Gram-negative bacteria causing infections in ICU patients, MYSTIC Program Brazil 2003. Gram-negative bacteria (n = 1,550) causing nosocomial infections were collected at 20 Brazilian centers. The central laboratory confirmed the identification and performed the susceptibility tests by Etest methodology (AB Biodisk, Solna, Sweden) for meropenem, imipenem, ciprofloxacin, ceftazidime, cefepime, cefotaxime, piperacillin/tazobactam, gentamicin, and tobramycin. Interpretation criteria used were according to National Committee for Clinical Laboratory Standards (NCCLS). Pseudomonas aeruginosa (30.3 percent) was the most frequent isolate, followed by E. coli (18.6 percent), Klebsiella pneumoniae (16.9 percent), Acitenobacter baumannii (8.8 percent), and Enterobacter cloacae (7.1 percent). Pseudomonas aeruginosa (n=470) isolates presented susceptibility rates of 64 percent to meropenem, 63.8 percent to piperacillin/tazobactam, 63.4 percent to amikacin, 58.7 percent to imipenem. Acitenobacter baumannii presented susceptibility rates to meropenem of 97.1 percent, and 73 percent to tobramycin. E. coli and K. pneumoniae were highly susceptible to both carbapenems.Carbapenem resistance among the Enterobacteriaceae is still rare in the region. Acitenobacter baumannii and P. aeruginosa presented elevated resistance rates to all antimicrobials. Since they play an important role in nosocomial infections in this environment, the use of empirical combination therapy to treat these pathogens may be justified.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Infección Hospitalaria
/
Bacterias Gramnegativas
/
Antibacterianos
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
America del Sur
/
Brasil
Idioma:
Inglés
Revista:
Braz. j. infect. dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2005
Tipo del documento:
Artículo
País de afiliación:
Brasil
/
Reino Unido
Institución/País de afiliación:
AstraZeneca Pharmaceuticals/GB
/
Fleury Institute/BR
Similares
MEDLINE
...
LILACS
LIS